Skip to content
Finance & Wealth

Ashley McEvoy's Net Worth: A Fact-Based Financial and Career Profile

In this article

As of 2026, Ashley McEvoy’s net worth is estimated to be between $30 million and $50 million. This valuation is primarily rooted in her 27-year career at Johnson & Johnson, where she served as Executive Vice President and Worldwide Chairman of MedTech, supplemented by her lucrative board membership at Procter & Gamble.

The Foundation of Executive Wealth: A 27-Year Tenure at Johnson & Johnson

To understand the financial profile of Ashley McEvoy, one must analyze the trajectory of her career within Johnson & Johnson (J&J). Joining the company in 1996, McEvoy represents a generation of corporate leaders who climbed the internal ladder through decades of consistent performance. In the world of executive compensation, longevity at a blue-chip, S&P 500 company is the most reliable driver of multi-million-dollar net worths.

For executives at McEvoy's level, wealth is rarely comprised of a simple cash salary. Instead, it is a complex tapestry of base pay, annual performance-based bonuses, and, most importantly, long-term incentive (LTI) plans. These LTI plans typically include Restricted Stock Units (RSUs) and Performance Share Units (PSUs) that vest over several years. Because McEvoy remained with J&J for nearly three decades, she benefited from the compounding effect of these grants and the general appreciation of J&J’s stock price over time.

The MedTech Leadership Era

McEvoy’s most significant financial gains occurred during her tenure as the leader of the MedTech segment (formerly known as Medical Devices). By the time she stepped down in late 2023, the MedTech division was a global powerhouse generating over $27 billion in annual revenue. Under her leadership, the division underwent a massive transformation, moving away from legacy products and toward high-growth areas like robotics, digital surgery, and heart failure technology.

The financial "heavy lifting" of her net worth was solidified through successful strategic moves, such as the $16.6 billion acquisition of Abiomed. Large-scale acquisitions and successful integration strategies are key performance indicators (KPIs) that boards use to justify top-tier executive compensation. When a segment leader successfully pivots a multibillion-dollar division toward higher margins, their variable compensation—often paid in stock—increases exponentially.

Analyzing Executive Compensation Structures

To build a fact-based profile of Ashley McEvoy's net worth, we must examine the public disclosures required by the U.S. Securities and Exchange Commission (SEC). Specifically, the "Proxy Statement" (Schedule 14A) filed annually by Johnson & Johnson provides a granular look at the earnings of its "Named Executive Officers" (NEOs).

Components of Annual Earnings

During her final years at J&J, McEvoy’s annual total compensation package generally fluctuated between $6 million and $9 million. A typical breakdown for an executive in her position includes:

  1. Base Salary: Usually ranging from $900,000 to $1.1 million. This is the fixed cash component.
  2. Annual Incentive (Bonus): Ranging from $1.5 million to $2.5 million, depending on whether the MedTech segment hit specific revenue and earnings-per-share (EPS) targets.
  3. Stock Awards: The largest portion, often valued at $3 million to $5 million annually. These awards are subject to vesting schedules, meaning the executive must remain with the company or meet performance goals to "own" the shares.
  4. Option Awards: Long-term rights to purchase stock at a set price, which become valuable if the company's stock price rises.

By 2026, the historical accumulation of these awards, combined with the dividends paid on held shares, forms the bedrock of her personal wealth. J&J has a long history of being a "Dividend King," having increased its dividend for over 60 consecutive years. For an executive holding hundreds of thousands of shares, the quarterly dividend payments alone can constitute a significant seven-figure annual income stream.

Ashley Graham Net Worth 2023: What Is The Model Worth?
Ashley Graham Net Worth 2023: What Is The Model Worth?

Strategic Board Positions and External Income

Beyond her primary career at Johnson & Johnson, Ashley McEvoy has expanded her financial profile through strategic appointments to the boards of other major corporations. The most notable of these is her seat on the Board of Directors for Procter & Gamble (P&G).

The Value of a P&G Board Seat

Serving on the board of a company like P&G is a highly prestigious and financially rewarding role. According to P&G’s proxy filings, non-employee directors receive a substantial annual retainer. This typically consists of:

  • Cash Retainer: Approximately $120,000 to $150,000 per year.
  • Equity Grants: Approximately $175,000 to $200,000 in P&G stock or restricted stock units annually.
  • Committee Fees: Additional payments for serving on or chairing specific committees, such as Audit or Compensation.

When these figures are compounded over several years of service, the board position adds several million dollars to an executive's net worth. Furthermore, these roles provide diversified exposure to different market sectors, protecting the executive’s wealth from being entirely tied to a single company's performance.

Estimated Compensation History (Fact-Based Estimates)

The following table outlines the estimated compensation for Ashley McEvoy during her peak years of leadership, based on historical SEC filings and industry benchmarks for EVP roles at Johnson & Johnson.

Year Role Base Salary (Est.) Stock & Option Awards Total Annual Comp
2020 EVP, Worldwide Chairman, MedTech $950,000 $5,200,000 $7,150,000
2021 EVP, Worldwide Chairman, MedTech $985,000 $5,800,000 $7,900,000
2022 EVP, Worldwide Chairman, MedTech $1,020,000 $6,100,000 $7,420,000
2023 EVP (Partial Year/Departure) $850,000* $4,500,000* $6,500,000*
2024-25 Board Member (P&G / Others) $150,000 $200,000 $350,000+

*Estimates reflect pro-rated salary and vesting schedules typical for executive departures.

The Impact of Market Performance and Dividends

A critical factor in the "fact-based" assessment of net worth is the performance of the underlying equity. Executives at McEvoy's level do not typically liquidate their entire holdings upon departure. Instead, they manage a portfolio of vested shares.

Between 2013 and 2023, Johnson & Johnson’s stock price saw significant growth, nearly doubling in value while consistently paying out dividends. For an executive who likely held 100,000 to 200,000 shares (including unvested units and options), the "paper wealth" fluctuated but remained in the tens of millions.

In addition to J&J and P&G, high-net-worth individuals of McEvoy’s stature often utilize private wealth management firms to diversify into real estate, private equity, and municipal bonds. While these private investments are not matters of public record, they are standard practice for maintaining and growing wealth post-retirement from a primary executive role.

Career Milestones Influencing Financial Value

Ashley McEvoy’s net worth is a direct reflection of the scale of the responsibilities she managed. In the corporate world, compensation is often pegged to the "size of the P&L" (Profit and Loss statement).

Leading the MedTech Rebranding

One of her most significant contributions was the 2022 rebranding of "Medical Devices" to "Johnson & Johnson MedTech." This was not merely a name change; it was a strategic overhaul to integrate data science and digital tools into surgical hardware. The success of this transition increased J&J's enterprise value, which in turn increased the value of the stock options held by McEvoy.

Navigating the COVID-19 Pandemic

During 2020 and 2021, the medical device industry faced unprecedented challenges as elective surgeries were postponed globally. McEvoy’s ability to manage the MedTech segment through this volatility—maintaining profitability and preparing for the "rebound" in surgical volumes—was a key factor in her high performance-based bonuses during those years. Boards reward stability in times of crisis, and McEvoy’s tenure provided exactly that.

Post-Departure Status and 2026 Outlook

When Ashley McEvoy announced her departure from Johnson & Johnson in October 2023, it marked the end of an era. At that time, she stated her intention to pursue new opportunities. In the years following (2024–2026), she has transitioned into the "plural career" phase typical of elite executives—balancing board seats, advisory roles, and potentially private equity partnerships.

By 2026, her net worth has likely stabilized. While she no longer receives the massive annual stock grants associated with an EVP role at a $400 billion company, her existing portfolio continues to generate wealth through market appreciation and dividends. Furthermore, her status as a high-ranking female executive in a traditionally male-dominated field (MedTech and Surgery) makes her a highly sought-after advisor for venture capital firms specializing in healthcare, which can lead to "carried interest" earnings—a significant wealth multiplier.

Frequently Asked Questions

How much of Ashley McEvoy's net worth is in cash?

It is unlikely that a majority of her net worth is in cash. Standard executive financial planning involves keeping 5% to 10% in liquid assets, with the remainder diversified in equities (J&J, P&G), fixed-income securities, and real estate. This structure optimizes for tax efficiency and long-term growth.

Does her net worth include her primary residence?

Most net worth estimates for public figures include the value of known real estate holdings. Executives of her level typically own high-value properties in regions like New Jersey (near J&J headquarters) or Florida. These properties can represent $5 million to $10 million of the total valuation.

How did her departure from J&J affect her wealth?

Departing a company often triggers "acceleration" or "forfeiture" clauses for stock. However, for a 27-year veteran leaving in good standing, most companies allow for continued vesting of shares or a retirement-based payout. Her wealth likely remained stable or grew due to the overall health of the stock market in the mid-2020s.

Is Ashley McEvoy the wealthiest female executive in healthcare?

While highly successful, she is among a peer group of wealthy female leaders like Karen Lynch (CVS Health) or Gail Boudreaux (Elevance Health). Her wealth is significant but consistent with the top tier of EVP-level executives in the global pharmaceutical and MedTech sectors.

What is her current source of income in 2026?

As of 2026, her income likely stems from three main sources: annual retainers and equity grants from board positions (like P&G), dividends from her accumulated stock portfolio, and potential consulting or advisory fees within the healthcare and private equity sectors.

Practical Takeaway for Professionals

The "fact-based profile" of Ashley McEvoy’s net worth serves as a blueprint for long-term wealth creation in the corporate sector. It demonstrates that true executive wealth is built through longevity, equity-based compensation, and strategic diversification via board roles. For those looking to emulate this path, the focus should not be on the starting salary but on the long-term incentive structures and the ability to manage increasingly larger P&L segments within a global organization.